Press Release: "Antidote Technologies Named as Finalist for Scrip Awards"
Digital health company has been nominated for two leading pharmaceutical industry awards, recognizing its technology and partnerships
New York and London (November 13, 2017) - Antidote Technologies, a digital health company dedicated to accelerating research by transforming the way patients connect with researchers, has been named as a finalist for the 13th Annual Scrip Awards. Antidote is shortlisted in two categories: “Community Partnership of the Year” and “Best Technological Development in Clinical Trials - Patient-Focused.” Winners will be announced at a ceremony held at the London Hilton on November 29, 2017.
The Scrip Awards provide the industry with the opportunity to recognize its highest achievers across the drug development spectrum — from novel deals, to new drug launches, to technological breakthroughs in clinical trials. The awards are hosted by Pharma Intelligence, an Informa business that provides international pharmaceutical news, analysis, and data services.
In the “Best Technological Development in Clinical Trials - Patient-Focused” category, Antidote has made the shortlist for its product Antidote Match, the first trial matching engine that uses structured eligibility criteria, proprietary algorithms, and machine learning to explore a patient’s eligibility for every trial. Antidote Match
launched with its first large partner in the summer of 2016 and currently powers clinical trial search for 210+ patient communities and health portals — bringing clinical trial awareness, matching, and access to more than 15 million patients a month.
“We are honored to be named finalists for the Scrip Awards in two categories that mean so much to us,” said Pablo Graiver, CEO and Founder of Antidote. “We pride ourselves on our technology, and rely on partnerships with incredible communities like JDRF to get that technology to patients where they are already looking for
help. We’re expanding our offerings every day and look forward to connecting many more patients in many more therapeutic areas to critical research.”
The company has been nominated a finalist in the “Community Partnership of the Year” category for its partnership with JDRF, the leading organization funding type 1 diabetes research. JDRF launched Antidote Match on their website as Clinical Trials Connection and continuously collaborates with Antidote on building clinical trial resources.
“From the day we launched of this partnership, it was clear there was high interest and a great need for the Clinical Trials Connection tool. Since then, more than 25,000 individuals have searched for trials on our site,” said Aaron Kowalski, Chief Mission Officer at JDRF. “By providing the matching tool, we are not only helping people with type 1 diabetes find clinical trials more easily; we are also helping to fill a gap in trial participation and drive research forward.”
This announcement comes on the heels of Antidote’s latest round of funding, led by Merck Global Health Innovation Fund, Merck’s venture capital arm. In September, Antidote attended the 7th Annual DPharm: Disruptive Innovations to Advance Clinical Trials conference, during which the company’s CEO Pablo Graiver gave a talk on their new model for patient centricity.
Antidote is a digital health company on a mission to accelerate the breakthroughs of new treatments by bridging the gap between medical research and the people who need it. In a world where 80% of clinical trials are delayed or closed due to lack of participants, Antidote use cutting-edge technology to match the right patients with the right trials, helping medical researchers make faster progress, and offering new treatment options to patients. Antidote Match, the company’s unique trial matching tool, currently powers clinical trial search for more than 210 patient communities and health portals — bringing clinical trial awareness, matching, and access to more than 15 million patients a month. Antidote was launched as TrialReach and is based in the US and UK. As of today, the company has raised $26M. For more information, please visit www.antidote.me.
JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested more than $2 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our six international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter: @JDRF.
Chief Patient Officer, Antidote
Director of Communications, Antidote